MLL t(4;11)(q21;q23) Qualitative Test
Comprehensive Genetic Testing for Leukemia Diagnosis
The MLL t(4;11)(q21;q23) Qualitative Test represents a cutting-edge molecular diagnostic approach for detecting specific genetic abnormalities associated with acute leukemias. This sophisticated test utilizes Real-Time PCR technology to identify the chromosomal translocation between the MLL gene on chromosome 11q23 and the AF4 gene on chromosome 4q21, providing clinicians with essential information for accurate diagnosis and treatment planning.
What Does the MLL t(4;11)(q21;q23) Test Measure?
This specialized genetic test specifically detects the presence of the t(4;11)(q21;q23) chromosomal translocation, which results in the fusion of the MLL (Mixed Lineage Leukemia) gene with the AF4 gene. This genetic abnormality creates an oncogenic fusion protein that disrupts normal cellular processes and contributes to the development of leukemia.
- Detection of MLL-AF4 fusion gene transcripts
- Identification of specific chromosomal breakpoints
- Qualitative assessment of translocation presence
- High-sensitivity molecular analysis
Who Should Consider This Test?
The MLL t(4;11)(q21;q23) Qualitative Test is particularly important for patients presenting with specific clinical scenarios:
- Infants and young children with suspected acute lymphoblastic leukemia (ALL)
- Patients with therapy-related myeloid neoplasms following previous cancer treatment
- Individuals with acute myeloid leukemia showing unusual clinical features
- Patients requiring precise genetic characterization for treatment planning
- Cases where conventional cytogenetic testing requires molecular confirmation
Clinical Symptoms and Indications
Patients who may benefit from this test often present with symptoms including unexplained fatigue, recurrent infections, easy bruising or bleeding, bone pain, fever, night sweats, and unexplained weight loss. The test is particularly crucial when these symptoms occur in infants or following previous chemotherapy or radiation treatment.
Benefits of MLL t(4;11)(q21;q23) Testing
Accurate Diagnosis and Prognosis
The detection of MLL rearrangements provides critical prognostic information, as these genetic abnormalities are associated with specific clinical outcomes and treatment responses. Patients with MLL translocations often require specialized treatment approaches.
Personalized Treatment Planning
Identifying the specific genetic abnormality allows healthcare providers to tailor treatment strategies to the individual’s genetic profile, potentially improving treatment efficacy and reducing unnecessary side effects.
Monitoring Disease Progression
This test serves as a baseline for monitoring treatment response and detecting minimal residual disease, enabling early intervention if needed.
Understanding Your Test Results
Positive Result Interpretation
A positive result indicates the presence of the MLL t(4;11)(q21;q23) translocation, confirming the genetic basis for the leukemia diagnosis. This finding typically correlates with specific clinical features and may influence treatment intensity and duration.
Negative Result Interpretation
A negative result suggests the absence of this specific translocation, which may indicate a different genetic subtype of leukemia requiring alternative diagnostic approaches and treatment strategies.
Clinical Correlation
All test results should be interpreted in the context of clinical findings, complete blood counts, bone marrow morphology, and other diagnostic studies by a qualified hematologist or oncologist.
Test Specifications and Pricing
| Test Parameter | Details |
|---|---|
| Test Name | MLL t(4;11)(q21;q23) Qualitative Test |
| Regular Price | $150 USD |
| Discount Price | $112 USD |
| Turnaround Time | 3-4 Days |
| Sample Type | Bone Marrow / Peripheral Blood (Transport Immediately) |
| Test Components | EDTA Vacutainer (2ml) |
| Testing Method | Real Time PCR |
Pre-Test Instructions and Requirements
The MLL t(4;11)(q21;q23) Qualitative Test requires a Doctor’s prescription for most cases. However, prescription requirements do not apply for surgery and pregnancy cases or individuals planning to travel abroad. Our experienced healthcare team will guide you through the sample collection process and ensure proper handling of your specimens.
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, Charlotte, San Francisco, Indianapolis, Seattle, Denver, Washington DC, Boston, El Paso, Nashville, Detroit, Oklahoma City, Portland, Las Vegas, Memphis, Louisville, Baltimore, and Milwaukee.
Take Control of Your Health Today
Early and accurate genetic testing can make a significant difference in leukemia management and treatment outcomes. Our state-of-the-art MLL t(4;11)(q21;q23) Qualitative Test provides the precise genetic information needed for informed medical decisions.
Ready to Schedule Your Test?
Contact our dedicated healthcare team today to schedule your MLL genetic testing. Call or WhatsApp us at +1(267) 388-9828 to book your appointment or discuss your testing needs with our genetic specialists. We’re committed to providing accessible, accurate genetic testing services to patients throughout the United States.
Don’t wait – take the first step toward comprehensive genetic understanding and personalized leukemia care today!
